Senseonics Holdings Inc. (SENS)
NASDAQ:SENS
Want to see SENS full AI Analyst Report?
SENS Stock Chart & Stats
$6.77
-$0.03(-6.68%)
At close: 4:00 PM EST
$6.77
-$0.03(-6.68%)
Day’s Range― - ―
52-Week Range$4.79 - $12.56
Previous CloseN/A
Volume3.00M
Average Volume (3M)1.01M
Market Cap
$330.97M
Enterprise Value$278.19M
Total Cash (Recent Filing)$64.64M
Total Debt (Recent Filing)$43.14M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 06, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,202,965
10 Day Avg. Volume774,195
30 Day Avg. Volume1,006,062
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue6.83
Enterprise Value/Gross Profit13.12
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$16.67Price Target Upside146.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.41
Revenue Forecast (FY)$62.33M
Bulls Say, Bears Say
Bulls Say
Product Integration And AdoptionFull market release of the product integrated with a popular automated insulin delivery system is expected to increase adoption among Type 1 patients and expand the addressable market.
Profitability And MarginsMaterial improvement in gross margins following the Ascensia transition supports a more sustainable path to margin expansion and improved profitability.
Regulatory ApprovalCE mark approval for Eversense 365 as the first year‑long continuous glucose monitoring system in the EU enables regulatory market access and supports European commercialization.
Bears Say
Clinician Adoption ConcernsSome clinicians reported concerns about consistent sensor placement and the sensor's visibility, which limited their willingness to prescribe the device.
Marketing Spend And Operating ExpensesPlanned continued heavy direct‑to‑consumer marketing and elevated operating expenses could pressure profitability and delay a clear path to positive earnings.
Valuation And Analyst SentimentShares appear fairly valued on an enterprise‑value‑to‑sales basis, supporting the analyst's Neutral rating and limiting upside from revaluation.
Senseonics Holdings News
SENS FAQ
What was Senseonics Holdings Inc.’s price range in the past 12 months?
Senseonics Holdings Inc. lowest stock price was $4.79 and its highest was $12.56 in the past 12 months.
What is Senseonics Holdings Inc.’s market cap?
Senseonics Holdings Inc.’s market cap is $330.97M.
When is Senseonics Holdings Inc.’s upcoming earnings report date?
Senseonics Holdings Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 72 days.
How were Senseonics Holdings Inc.’s earnings last quarter?
Senseonics Holdings Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.686 by -$0.024.
Is Senseonics Holdings Inc. overvalued?
According to Wall Street analysts Senseonics Holdings Inc.’s price is currently Undervalued.
Does Senseonics Holdings Inc. pay dividends?
Senseonics Holdings Inc. does not currently pay dividends.
What is Senseonics Holdings Inc.’s EPS estimate?
Senseonics Holdings Inc.’s EPS estimate is -0.61.
How many shares outstanding does Senseonics Holdings Inc. have?
Senseonics Holdings Inc. has 52,202,965 shares outstanding.
What happened to Senseonics Holdings Inc.’s price movement after its last earnings report?
Senseonics Holdings Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.686. Following the earnings report the stock price went down -6.157%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc.?
Currently, no hedge funds are holding shares in SENS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.67 (146.18% Upside)
$16.67 (146.18% Upside)
Blogger Sentiment
Bullish
SENS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $326.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.61%
12-Months-Change
Fundamentals
Return on Equity
-130.00%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
SENS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.View all SENS earnings summariesSENS Stock 12 Month Forecast
Average Price Target
$16.67
▲(146.18% Upside)
Technical Analysis
Ownership Overview
5.90% Insiders
4.20% Mutual Funds
5.46% Other Institutional Investors
80.89% Public Companies and
Individual Investors